Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

In conclusion, Dr Khushalani notes much progress in improving melanoma survivorship but cautions emerging immunotherapies will likely bring more toxicities requiring adept management. He foresees greater predictive modeling and molecular testing enabling personalized toxicity risk assessments to guide informed treatment decisions. Dr Shariff expects cancer will follow other chronic diseases with greatly improved long-term outcomes thanks to advancing therapies, necessitating increased focus on survivorship care quality. Dr Moslehi closes by celebrating progress in metastatic melanoma thanks to oncology innovations, requiring a collaborative multidisciplinary approach across specialties to provide comprehensive patient care going forward.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.